Lost to treatment · people with both severe mental illness and substance misuse
It is very uncertain whether skills training changes leaving the study early: Lost to treatment compared with standard care (very low certainty).
1 finding from 1 review
Lost to treatment · people with both severe mental illness and substance misuse
Cognitive behavioural therapy + motivational interviewing showed no clear difference in leaving the study early: Lost to treatment compared with standard care (low certainty).
1 finding from 1 review
Lost to treatment · people with both severe mental illness and substance misuse
1 finding from 1 review
Lost to treatment · people with both severe mental illness and substance misuse
It is very uncertain whether non‐integrated models of care ‐ Assertive community treatment… changes leaving the study early: Lost to treatment compared with standard care (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS changes behaviour: Leaving the study early (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS changes behaviour: Leaving the study early (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review